Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by Vetr from a “buy” rating to a “strong-buy” rating in a research note issued on Tuesday, January 30th. The brokerage currently has a $23.57 target price on the stock. Vetr‘s price objective points to a potential upside of 21.93% from the company’s previous close.
Other equities research analysts have also issued reports about the stock. BTIG Research raised their price objective on shares of Teva Pharmaceutical Industries to $20.00 in a report on Friday, December 15th. ValuEngine upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Evercore ISI set a $38.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Wednesday, October 25th. Goldman Sachs Group raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Friday, December 15th. Finally, Citigroup raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Thursday, January 4th. Ten analysts have rated the stock with a sell rating, sixteen have given a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $21.26.
Teva Pharmaceutical Industries (TEVA) opened at $19.33 on Tuesday. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries has a fifty-two week low of $10.85 and a fifty-two week high of $37.94. The company has a market cap of $19,890.00, a P/E ratio of -1.12, a PEG ratio of 1.43 and a beta of 0.59.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.14. The company had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.29 billion. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 14.52%. The firm’s quarterly revenue was down 15.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.38 EPS. research analysts anticipate that Teva Pharmaceutical Industries will post 2.69 earnings per share for the current year.
A number of institutional investors and hedge funds have recently made changes to their positions in TEVA. Two Sigma Advisers LP acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth about $118,487,000. Franklin Resources Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 8.2% during the fourth quarter. Franklin Resources Inc. now owns 79,488,139 shares of the company’s stock worth $1,506,309,000 after buying an additional 6,009,897 shares in the last quarter. OppenheimerFunds Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $69,418,000. Macquarie Group Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 350.3% during the third quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock worth $77,587,000 after buying an additional 3,429,448 shares in the last quarter. Finally, Capital World Investors grew its holdings in shares of Teva Pharmaceutical Industries by 41.9% during the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock worth $367,686,000 after buying an additional 3,268,200 shares in the last quarter. Institutional investors own 51.93% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/15/teva-pharmaceutical-industries-teva-upgraded-by-vetr-to-strong-buy.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.